Class / Patent application number | Description | Number of patent applications / Date published |
514294000 | Ring nitrogen is shared by two of the cyclos | 60 |
20080255178 | Azaadamantane Ester and Carbamate Derivatives and Methods of Use Thereof - The invention relates to compounds that are substituted azaadamantane ester and carbamate derivatives, compositions comprising such compounds, and methods of using such compounds and compositions. | 10-16-2008 |
20080255179 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof - The invention relates to compounds that are acetamide and carboxamide derivatives of azaadamantane, compositions comprising such compounds, and methods of using such compounds and compositions. | 10-16-2008 |
20080255180 | 4-Substituted Azaadamantane Derivatives and Methods of Use Thereof - The invention relates to compounds that are 4-substituted azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions. | 10-16-2008 |
20080262023 | Aminomethyl Azaadamantane Derivatives and Methods of Use Thereof - The invention relates to compounds that are substituted aminomethyl azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions. | 10-23-2008 |
20080262024 | RIFAXIMIN COMPOSITIONS AND METHOD OF USE - Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use. | 10-23-2008 |
20080269275 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders - Compounds of Formula I | 10-30-2008 |
20080269276 | COMPOSITIONS USEFUL FOR TREATING IRRITABLE BOWEL SYNDROME - The present invention relates to a method of treating irritable bowel syndrome with constipation (IBS-c) or irritable bowel syndrome with alternating constipation and diarrhea (IBS-a) in a subject in need of treatment. The method comprises administering to said subject a therapeutically effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof. | 10-30-2008 |
20080319000 | Use of 3,1IB-Cis-Dihydrotetrabenazine for the Treatment of Symptoms of Huntingtons Disease - The invention provides 3,11b-cis-dihydrotetrabenazine for use in halting or slowing the progress of one or more symptoms of Huntington's disease in a patient, and more particularly a symptom selected from involuntary movements such as involuntary chorea, tremors and twitches, and degeneration in gait. | 12-25-2008 |
20090258895 | PHARMACEUTICAL FORMULATION AND PROCESS COMPRISING A SOLID DISPERSION OF MACROLIDE (TACROLIMUS) - The present invention relates to a pharmaceutical formulation and process for preparing the same comprising an oral dosage formulation, such as a capsule formulation, of a macrolide compound, such as tacrolimus, wherein the capsule formulation contains both a solid dispersion of the macrolide along with a non-dispersed form of the macrolide. The pharmaceutical formulation according to the invention is bioequivalent to the FDA approved product according to a bioavailability study conducted in humans. | 10-15-2009 |
20090286825 | Indole derivatives as crth2 receptor antagonists - Compounds according to formula (I) wherein the radicals R | 11-19-2009 |
20090306122 | SUBSTITUTED TETRAHYDROPYRROLOQUINOLINE DERIVATIVES AS KINASE MODULATORS, ESPECIALLY OF TYROSINE AND RAF KINASES - Compound of the formula (I), in which X, R | 12-10-2009 |
20100063086 | PHARMACEUTICAL COMPOUNDS - This application describes method of treating dementia and cognitive deficits associated with dementia that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof. | 03-11-2010 |
20100087475 | PHARMACEUTICAL COMPOUNDS - This application describes substituted 1,3,4,6,7,11b-hexahydro-benzo(a)quinolizine compounds, pharmaceutical compositions containing them, processes for making them and their therapeutic methods. | 04-08-2010 |
20100087476 | PHARMACEUTICAL COMPOUNDS - This application describes methods of treatment and/or prophylaxis of asthma that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof. | 04-08-2010 |
20100234415 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS - Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma. | 09-16-2010 |
20100273824 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES - The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. | 10-28-2010 |
20110003844 | REGULATION OF CARDIAC CONTRACTILITY AND HEART FAILURE PROPENSITY - The methods and compositions of the present invention find use in altering expression of PKCα in transgenic animals. The compositions of the invention include isolated transgenic animal cells, transgenic tissue, transgenic animals, and transgenic mice. The transgenic animals of the invention exhibit altered PKCα activity. The methods allow generation of transgenic animals with altered expression of PKCα. The invention allows modulation of cardiac contractility. In particular, the invention provides a method for altering the susceptibility of a transgenic animal to cardiomyopathy. A transgenic animal of the invention finds use in identifying anti-cardiomyopathic compounds. | 01-06-2011 |
20110039877 | USE OF 3, 11B-CIS-DIHYDROTETRABENAZINE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND AUTOIMMUNE MYELITIS - The invention provides a compound for use in treating multiple sclerosis wherein the compound is a 3, 11b-cis-dihydrotetrabenazine of the formula (Ia): or a pharmaceutically acceptable salt thereof. | 02-17-2011 |
20110092535 | Novel Epilepsy Treatment - The present invention resides in the use of a 5-HT3 receptor antagonist as medicament for the treatment of temporal lobe epilepsy associated with hippocampal sclerosis (TLE-HS) in a human patient. Tropisetron or Dolasetro are the preferred compounds. | 04-21-2011 |
20110118300 | GLUCOSE METABOLISM MODULATING COMPOUNDS - The present invention provides, inter alia, dihydropyridone compounds and compositions, including analogs of a vesicular monoamine transporter type 2 (VMAT2) antagonist. The present invention also provides methods of using such compounds/analogs for modulating glucose levels, and/or preventing, treating, or ameliorating the effects of diabetes and hyper-glycemia. | 05-19-2011 |
20110118301 | Amino-Aza-Adamantane Derivatives and Methods of Use - The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. | 05-19-2011 |
20110160242 | Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same - The present invention relates to a form 1 and form 2 polymorph of (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin- | 06-30-2011 |
20110160243 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer. | 06-30-2011 |
20110172263 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS - Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma. | 07-14-2011 |
20110190333 | DIHYDROTETRABENANZINE FOR THE TREATMENT OF ANXIETY - The invention provides a 3,11b-cis-dihydrotetrabenazine of the formula (Ib): or a pharmaceutically acceptable salt thereof for use in the prophylaxis or treatment of anxiety. | 08-04-2011 |
20110201641 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS - The compound (+) {7R-[[(4-fluorophenyl)sulfonyl] (methyl)ammo]-6,7,8,9-tetrahydropyrido[1,2-a]mdol-10-yl}acetic acid and pharmaceutically acceptable salts thereof are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-meidated diseases such as asthma. | 08-18-2011 |
20110212989 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES - Therapeutic method of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), | 09-01-2011 |
20110257220 | 3,11 b-cis-Dihydrotetrabenazine for the Treatment of Schizophrenia and Other Psychoses - The invention provides the use of 3,11b-cis-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prophylaxis or treatment of schizophrenia and other psychoses. | 10-20-2011 |
20120015972 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES - The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. That is, the present invention relates to indolizine derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, salts thereof or the like. In the formula, ring U represents aryl or heteroaryl; R | 01-19-2012 |
20120077839 | SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUIN- OLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO - Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1- | 03-29-2012 |
20120190706 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF - The invention relates to compounds that are acetamide and carboxamide derivatives of azaadamantane, compositions comprising such compounds, and methods of using such compounds and compositions. | 07-26-2012 |
20120196890 | 4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF - The invention relates to compounds that are 4-substituted azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions. | 08-02-2012 |
20120245195 | NOVEL MONOHYDRATE OF AZAADAMANTANE DERIVATIVES - The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1 | 09-27-2012 |
20120252836 | 1,3-Dioxanes and Their Uses - The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. | 10-04-2012 |
20120316193 | PROTEOSTASIS REGULATORS - The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds. | 12-13-2012 |
20130102626 | TARGETED NITROXIDE AGENTS - Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation. | 04-25-2013 |
20130150398 | Indole Derivatives as CRTH2 Receptor Antagonists - Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma. | 06-13-2013 |
20130184307 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. | 07-18-2013 |
20130197026 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA - The disclosure provides methods of treating glioblastoma, methods of screening for compounds that treat glioblastoma, and pharmaceutical compositions useful the treatment of glioblastoma. | 08-01-2013 |
20130267552 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY - This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in particular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia. | 10-10-2013 |
20130267553 | LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON - The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | 10-10-2013 |
20130296360 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 - The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. | 11-07-2013 |
20130317054 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE - An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, or a pharmaceutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof. | 11-28-2013 |
20130317055 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE - An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof. | 11-28-2013 |
20130317056 | NEURONAL NICOTINIC AGONISTS AND METHODS OF CORRELATING COMT SNPS - This application is directed to a-neuronal nicotinic receptor agonists selective for α7-subtype that are useful for improving cognition impairment in patients having schizophrenia, a schizophreniform disorder or a related schizophrenia spectrum psychotic disorder. Compounds and compositions containing such compounds, and methods of using such compound and compositions are described herein. | 11-28-2013 |
20140206712 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 - The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. | 07-24-2014 |
20140206713 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 - The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. | 07-24-2014 |
20140249176 | PROTEIN SYNTHESIS REQUIRED FOR LONG-TERM MEMORY IS INDUCED BY PKC ACTIVATION ON DAYS PRECEDING ASSOCIATIVE LEARNING - The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC. | 09-04-2014 |
20140296280 | PURES-(-)-9-FLUORO-6,7-DIHYDRO-8-(4-HYDROXYPIPERIDIN-1-YL)-5-METHYL-1-OXO-- 1H,-5H-BENZO[I,J]QUINOLIZINE-2- CARBOXYLIC ACID L-ARGININE SALT TETRAHYDRATE AND A PROCESS FOR ITS PREPARATION - Pure S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,-5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt tetrahydrate and a process for its preparation is disclosed. | 10-02-2014 |
20140350044 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 - The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. | 11-27-2014 |
20150080426 | BENZOQUINOLINE INHIBITORS OF VMAT 2 - The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. | 03-19-2015 |
20150080427 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 - The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. | 03-19-2015 |
20150313891 | NEURONAL NICOTINIC AGONISTS AND METHODS OF USE - An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, or a pharmaceutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof. | 11-05-2015 |
20150328207 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 - The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. | 11-19-2015 |
20150328208 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER - The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent. | 11-19-2015 |
20150336966 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer. | 11-26-2015 |
20160030414 | BENZOQUINOLINE INHIBITORS OF VMAT 2 - The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. | 02-04-2016 |
20160058751 | COMPOSITION AND METHOD FOR TREATING CANCER - The present disclosure relates to a pharmaceutical composition and a kit to treat cancer. The disclosure provides a combination of compounds for use in the treatment of cancer. The disclosure further provides a process of preparing the composition and a method of treating a cancer associated with a RAS mutation or a RAS mutation along with any other mutation. | 03-03-2016 |
20160068526 | BENZOQUINOLONE INHIBITORS OF VMAT2 - The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. | 03-10-2016 |
20160090383 | ANTIBACTERIAL PHTHALIDE DERIVATIVES - The invention relates to antibacterial compounds of formula I | 03-31-2016 |